The efficacy and safety of uniportal video-assisted thoracic surgery on the treatment for stage II-III tuberculous empyema: a single-arm clinical retrospective study from 2016 to 2021 in a thoracic surgery center in China
Abstract Background Surgery is an important adjuvant treatment for tuberculous empyema(TE). We thus conducted a single arm-clinical retrospective study of stage II-III TE patients who underwent uniportal video-assisted thoracic surgery (Uni-VATS) over a 5-year period to evaluate the efficacy and saf...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-11-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12890-022-02182-w |
| _version_ | 1811223511724720128 |
|---|---|
| author | Wenwen Sun Guidong Yin Haomin Cai Yiming Zhou Jin Gu Shanhao Chen Lin Fan |
| author_facet | Wenwen Sun Guidong Yin Haomin Cai Yiming Zhou Jin Gu Shanhao Chen Lin Fan |
| author_sort | Wenwen Sun |
| collection | DOAJ |
| description | Abstract Background Surgery is an important adjuvant treatment for tuberculous empyema(TE). We thus conducted a single arm-clinical retrospective study of stage II-III TE patients who underwent uniportal video-assisted thoracic surgery (Uni-VATS) over a 5-year period to evaluate the efficacy and safety of surgery on TE, so as to provide the evidence for the optimal clinical strategies. Methods Patients diagnosed as TE with withdrawal of anti-tuberculosis-VATS were retrospectively enrolled from January 2016 to December 2021. All patients were followed up untill 12 months after withdrawal of anti-tuberculosis treatment (ATT). Clinical characteristics and surgical details were observed and analyzed to evaluate the efficacy and safety of the minimally invasive surgery. Results Totally 439 cases met included criteria were enrolled, no deaths were reported. The mean operative time was 2.6 (1.9, 4.3) hours and the mean intraoperative blood loss was 356 (240, 940) ml. Blood transfusion was performed in 20.50% (90/439) of patients and additional pneumonectomy was occurred in 9.89%(37/439)of patients .The mean postoperative drainage time was 12 (7, 49) days and the mean hospital stay was 6 (4,12) days. All stage II TE achieved complete lung re-expansion after surgery while 84.22%(315/374) of stage III achieved complete lung re-expansion, p 0.00. 15.78% (59/374) of stage III TE achieved incomplete re-expansion, 4 of which underwent a second decortication by Uni-VATS. Recurrences rate was 2.96% (13/439), including 11 cases of early recurrence and 2 cases of late recurrence at TE stage III, 5 of which underwent a second decortication by Uni-VATS. Conclusion Uni-VATS is highly effective safe and minimally invasive for patients with TE, which could be recommended as the mainstream operation in areas with high TB burden. |
| first_indexed | 2024-04-12T08:33:54Z |
| format | Article |
| id | doaj.art-5b718dd00af54d22beb8b82eb52de5c0 |
| institution | Directory Open Access Journal |
| issn | 1471-2466 |
| language | English |
| last_indexed | 2024-04-12T08:33:54Z |
| publishDate | 2022-11-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pulmonary Medicine |
| spelling | doaj.art-5b718dd00af54d22beb8b82eb52de5c02022-12-22T03:40:04ZengBMCBMC Pulmonary Medicine1471-24662022-11-012211810.1186/s12890-022-02182-wThe efficacy and safety of uniportal video-assisted thoracic surgery on the treatment for stage II-III tuberculous empyema: a single-arm clinical retrospective study from 2016 to 2021 in a thoracic surgery center in ChinaWenwen Sun0Guidong Yin1Haomin Cai2Yiming Zhou3Jin Gu4Shanhao Chen5Lin Fan6Shanghai Clinic and Research Center of Tuberculosis, Department of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of MedicineDepartment of Thoracic Surgery, Changchun Infectious Disease Hospital,Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of MedicineDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of MedicineShanghai Clinic and Research Center of Tuberculosis, Department of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of MedicineShanghai Clinic and Research Center of Tuberculosis, Department of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of MedicineShanghai Clinic and Research Center of Tuberculosis, Department of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of MedicineAbstract Background Surgery is an important adjuvant treatment for tuberculous empyema(TE). We thus conducted a single arm-clinical retrospective study of stage II-III TE patients who underwent uniportal video-assisted thoracic surgery (Uni-VATS) over a 5-year period to evaluate the efficacy and safety of surgery on TE, so as to provide the evidence for the optimal clinical strategies. Methods Patients diagnosed as TE with withdrawal of anti-tuberculosis-VATS were retrospectively enrolled from January 2016 to December 2021. All patients were followed up untill 12 months after withdrawal of anti-tuberculosis treatment (ATT). Clinical characteristics and surgical details were observed and analyzed to evaluate the efficacy and safety of the minimally invasive surgery. Results Totally 439 cases met included criteria were enrolled, no deaths were reported. The mean operative time was 2.6 (1.9, 4.3) hours and the mean intraoperative blood loss was 356 (240, 940) ml. Blood transfusion was performed in 20.50% (90/439) of patients and additional pneumonectomy was occurred in 9.89%(37/439)of patients .The mean postoperative drainage time was 12 (7, 49) days and the mean hospital stay was 6 (4,12) days. All stage II TE achieved complete lung re-expansion after surgery while 84.22%(315/374) of stage III achieved complete lung re-expansion, p 0.00. 15.78% (59/374) of stage III TE achieved incomplete re-expansion, 4 of which underwent a second decortication by Uni-VATS. Recurrences rate was 2.96% (13/439), including 11 cases of early recurrence and 2 cases of late recurrence at TE stage III, 5 of which underwent a second decortication by Uni-VATS. Conclusion Uni-VATS is highly effective safe and minimally invasive for patients with TE, which could be recommended as the mainstream operation in areas with high TB burden.https://doi.org/10.1186/s12890-022-02182-wTuberculous empyemaUniportal video-assisted thoracic surgeryAdverse reactionsTreatment outcome |
| spellingShingle | Wenwen Sun Guidong Yin Haomin Cai Yiming Zhou Jin Gu Shanhao Chen Lin Fan The efficacy and safety of uniportal video-assisted thoracic surgery on the treatment for stage II-III tuberculous empyema: a single-arm clinical retrospective study from 2016 to 2021 in a thoracic surgery center in China BMC Pulmonary Medicine Tuberculous empyema Uniportal video-assisted thoracic surgery Adverse reactions Treatment outcome |
| title | The efficacy and safety of uniportal video-assisted thoracic surgery on the treatment for stage II-III tuberculous empyema: a single-arm clinical retrospective study from 2016 to 2021 in a thoracic surgery center in China |
| title_full | The efficacy and safety of uniportal video-assisted thoracic surgery on the treatment for stage II-III tuberculous empyema: a single-arm clinical retrospective study from 2016 to 2021 in a thoracic surgery center in China |
| title_fullStr | The efficacy and safety of uniportal video-assisted thoracic surgery on the treatment for stage II-III tuberculous empyema: a single-arm clinical retrospective study from 2016 to 2021 in a thoracic surgery center in China |
| title_full_unstemmed | The efficacy and safety of uniportal video-assisted thoracic surgery on the treatment for stage II-III tuberculous empyema: a single-arm clinical retrospective study from 2016 to 2021 in a thoracic surgery center in China |
| title_short | The efficacy and safety of uniportal video-assisted thoracic surgery on the treatment for stage II-III tuberculous empyema: a single-arm clinical retrospective study from 2016 to 2021 in a thoracic surgery center in China |
| title_sort | efficacy and safety of uniportal video assisted thoracic surgery on the treatment for stage ii iii tuberculous empyema a single arm clinical retrospective study from 2016 to 2021 in a thoracic surgery center in china |
| topic | Tuberculous empyema Uniportal video-assisted thoracic surgery Adverse reactions Treatment outcome |
| url | https://doi.org/10.1186/s12890-022-02182-w |
| work_keys_str_mv | AT wenwensun theefficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina AT guidongyin theefficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina AT haomincai theefficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina AT yimingzhou theefficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina AT jingu theefficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina AT shanhaochen theefficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina AT linfan theefficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina AT wenwensun efficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina AT guidongyin efficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina AT haomincai efficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina AT yimingzhou efficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina AT jingu efficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina AT shanhaochen efficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina AT linfan efficacyandsafetyofuniportalvideoassistedthoracicsurgeryonthetreatmentforstageiiiiituberculousempyemaasinglearmclinicalretrospectivestudyfrom2016to2021inathoracicsurgerycenterinchina |